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Objectives
By the end of this session, participants will be able to:
1. Discuss the team involved in creating the ACC/AHA guidelines on
the treatment of blood cholesterol to reduce atherosclerotic
cardiovascular risk in adults and the context for their
recommendations,
2. Discuss the evidence base behind the ACA/AHA
recommendations that are most relevant to family physicians,
and
3. Participate in large group case reviews that highlight the
important changes recommended by the ACA/AHA guidelines.

Conflicts of Interest
• None to report
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The Guidelines

Scope of the guideline
• Treatment of blood cholesterol
to REDUCE
Atherosclerotic Cardiovasular Disease (ASCVD) Risk
in adults
• Not comprehensive lipid management

The Guidelines‐ who was involved?
• Expert Panel ‐ 13 members, 3 ex‐officio members
• Primary care physicians, cardiologists, endocrinologists, and experts in
clinical lipidology, clinical trials, cardiovascular epidemiology, and guideline
development

• Conflicts of interest
• Disclosed in advance of the deliberations
• Members with conflicts recused themselves where a conflict might exist
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The Guidelines‐ who was involved?
• Started at the NHLBI ATP IV Panel
became the ACC/AHA guideline Expert Panel
• Lit review
• Performed by independent contractors
• Some assistance from expert panel

• Only RCT’s, systematic reviews with fair to good methodology
included

Evidence taxonomy

Evidence taxonomy,
part dieux
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Key Recommendations
• No more treat‐to‐target
• “No recommend for or against using specific LDL or non‐HDL targets for
primary or secondary prevention of ASCVD”

• Statins are the key – intensity levels
• No recs:
• Statins for NYHA heart failure II‐IV
• Statins for pts on dialysis

Controversy: Why no treat to target?
• ASCVD reduction is proportional to LDL‐C reduction

FROM

STATINS
• More potent statins = more risk reduction
• Higher pre‐statin risk = more benefit from statin

Controversy: Why no treat to target?
• Treating to target has resulted in:

•Over treating
• Under

low

risk

treating high risk
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Key Recs‐

Statin intensity

Specific statins and doses are noted in bold that were evaluated in RCTs. All of these RCTs demonstrated a
reduction in major cardiovascular events. Statins and doses that are approved by the U.S. FDA but were not
tested in the RCTs reviewed are listed in italics.
*Individual responses to statin therapy varied in the RCTs and should be expected to vary in clinical practice.
There might be a biologic basis for a less‐than‐average response.

Key Recs‐ 4 Major Statin Benefit Groups
Group

Statin intensity

Evidence

Women & men with clinical ASCVD*

High‐intensity (mod‐
intensity if 75+ y/o)

IA

*Clinical ASCVD includes acute coronary syndromes, history of MI, stable or
unstable angina, coronary or other arterial revascularization, stroke, TIA, or
peripheral arterial disease presumed to be of atherosclerotic origin.

Key Recs‐ 4 Major Statin Benefit Groups
Group

Statin intensity

Evidence

Women & men with clinical ASCVD*

High‐intensity (mod‐
intensity if 75+ y/o)

IA

Adults ≥21 years of age with primary LDL–C
≥190 mg/dL

High‐intensity

IB

*Clinical ASCVD includes acute coronary syndromes, history of MI, stable or
unstable angina, coronary or other arterial revascularization, stroke, TIA, or
peripheral arterial disease presumed to be of atherosclerotic origin.
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Key Recs‐ 4 Major Statin Benefit Groups
Group

Statin intensity

Evidence

Women & men with clinical ASCVD*

High‐intensity (mod‐
intensity if 75+ y/o)

IA

Adults ≥21 years of age with primary LDL–
C ≥190 mg/dL

High‐intensity

IB

Adults 40 to 75 years of age with diabetes
mellitus and no clinical ASCVD

Mod‐ intensity

IA

‐ If ASCVD risk ≥7.5%

High‐intensity

IIa B

*Clinical ASCVD includes acute coronary syndromes, history of MI, stable or
unstable angina, coronary or other arterial revascularization, stroke, TIA, or
peripheral arterial disease presumed to be of atherosclerotic origin.

Key Recs‐ 4 Major Statin Benefit Groups
Group

Statin intensity

Evidence

Women & men with clinical ASCVD* <75 y/o

High‐intensity

IA

Adults ≥21 years of age with primary LDL–C
≥190 mg/dL

High‐intensity

IB

Adults 40 to 75 years of age with diabetes
mellitus and no clinical ASCVD

Mod‐ intensity

IA

‐ If ASCVD risk ≥7.5%

High‐intensity

IIa B

Adults 40 to 75 years of age with LDL–C 70 to
189 mg/dL, without clinical ASCVD* or
diabetes and a 10‐year ASCVD risk ≥7.5%

Mod‐to‐high

IA

*Clinical ASCVD includes acute coronary syndromes, history of MI, stable or
unstable angina, coronary or other arterial revascularization, stroke, TIA, or
peripheral arterial disease presumed to be of atherosclerotic origin.

Mr. Paul Jones
• New patient to your practice – 64 y/o
• PMH: HTN, allergic rhinitis, h/o fem‐pop bypass
• SH: Rare EtOH, former tob‐ 2 PPD, quit 5 years ago, exercises daily for
last 3 years
• Rx: HCTZ/lisinopril, fluticasone nasal, ASA
• TC: 185, LDL: 125, TG’s: 135, HDL: 46
• Does Mr. Jones need statin?
• If so, what intensity?
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Mrs. Juanita Morales
• 35 y/o newly diagnosed diabetic
• PMH: Overweight, hypothyroidism
• SH: Rare EtOH, smokes 1 PPD, does not exercise
• Rx: metformin BID starting today
• TC: 185, LDL: 105, TG’s: 270, HDL: 40; A1c‐ 7.1%
• Does Mrs. Morales need a statin?
• Intensity?

Defining risk
• Framingham
• Included mostly white men
• Cardiac outcomes only

• Expert panel wanted :
• 10‐year ASCVD risk
• Broader racial/gender profile



Definiton 10‐year ASCVD risk:
“First occurrence nonfatal and fatal MI, and
nonfatal and fatal stroke”

“Pooled Cohorts Equations” Calculator
• Complete risk data from clinical trials for:
• Black/white (non‐Hispanic)
• Men/women
• Includes 10‐year ASCVD risk (“first occurrence nonfatal and fatal MI, and
nonfatal and fatal stroke”)

• http://my.americanheart.org/cvriskcalculator
• Online tool
• Android app
• i App
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Why 7.5% ASCVD risk???
• Pooled cohort equations include broader defn ASCVD
• 7.5% chosen based on risk/benefit analysis:

statin benefit >> statin risk
…in patients with > 7.5% risk

Incidence of severe statin reactions
Adverse Event

Incidence

New‐onset DM2‐ high‐intensity statin

0.3*

‐ mod‐intensity statin

0.1*

Myopathy

0.01*

Hemorrhagic stroke

0.01*

Acute Liver Failure (from statin)
Acute Liver Failure (idiopathic)

0.2 cases/million
people in US
0.5‐1.0
cases/million

*cases per 100 statin-treated individuals per yr

Statin Myopathy
• Other sources report rates as high as 10%
• Severity is the key

• Fernandez G, Spatz ES, Jablecki C, Phillips PS.Statin myopathy: a
common dilemma not reflected in clinical trials. Cleve Clin J Med.
2011.;78(6):393‐403
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Controversy: Calculator
• Only ages 40‐75
• 75+ qualify for statin (>7.5% risk) based on age alone
• Consider life expectancy
• Recall lower statin‐intensity for 75+

• DO NOT USE with post‐treatment numbers
• DO NOT USE if clinical ASCVD exists
• Watch for changes near thresholds, esp in low‐risk individuals
• Same problems exist with any calculator

Remember Mrs. Juanita Morales?
• Let’s imagine that she’s 40 y/o
• Newly diagnosed diabetic

• PMH: Overweight, hypothyroidism
• SH: Rare EtOH, smokes 1 PPD, does not exercise
• Rx: metformin BID starting today
• SBP 135; TC: 185, LDL: 105, TG’s: 270, HDL: 40
• Does Mrs. Morales need a statin?
• Intensity?
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Controversy: big changes in risk from
small changes in data

Big thresholds
• Smoking vs. non‐smoking

• BP thresholds (< 120 vs. 120‐140 vs. 140+)
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The Circle of (a guideline’s) Life
• Did not review evidence published after 2011

• An update is already underway

Questions so far?

Table of Contents: Managing rx
• Monitoring statins with blood work
• What to do with muscle symptoms
• Non‐statins
• Cases
Summary

12

3/17/2014

Blood work‐ Before starting statin
• Check fasting lipid panel
• If TG > 500 or LDL > 190, look for secondary causes

• Check ALT
• Evaluate and treat before starting if > 3x upper limit normal

• A1c for DM2 screening (if DM2 status not known)
• Maybe CK (more to come)

Statin monitoring‐ Lipids
• Initial fasting lipid panel
• Second lipid panel 4 ‐ 12 wks after statin
• To determine a patient’s adherence (IA)

• Thereafter, q 3 ‐ 12 months as clinically indicated
• Statin and lifestyle regimens needed for ASCVD risk reduction

• Use max appropriate intensity of statin that does not cause adverse
effects (IB)

Statin Adverse Effects
• Predisposing characteristics:
•
•
•
•
•

Comorbidities, including impaired renal or hepatic function
History of previous statin intolerance or muscle disorders
Unexplained ALT elevations >3x Upper Limit Normal (ULN)
Genetics/drugs affecting statin metabolism
>75 years of age

• Other factors to consider:
• History of hemorrhagic stroke
• Asian ancestry (consider lower intensity)
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Statin Monitoring‐ CK
• No routine CK monitoring
• Baseline CK reasonable for high risk of myopathy:
• Personal or FHx of statin intolerance or muscle disease
• Clinical presentation
• Concomitant drug therapy that increases risk

• During statin therapy check CK if:
• Muscle symptoms, including pain, tenderness, stiffness, cramping, weakness,
or generalized fatigue

Statin Monitoring‐ LFTs


If baseline normal, no routine ALT monitoring
• Trials don’t support it
• FDA recommends same

• Monitor ALT q6 mos if non‐statins added (IB)
• During statin therapy, check ALT if:
• Symptoms suggesting hepatotoxicity arise (e.g., unusual fatigue or weakness, loss
of appetite, abdominal pain, dark‐colored urine or yellowing of the skin or sclera).

Summary

Table of Contents: Managing rx
• Monitoring statins with blood work
• What to do with muscle symptoms
• Non‐statins
• Cases
Summary
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Troubleshooting‐ Muscle Sx’s
• If mild to mod muscle sx’s during statin therapy:
• Discontinue statin until sx’s evaluated
• Look for other conditions that might increase the risk for muscle symptoms
(e.g. hypothyroidism, renal or hepatic issue, rheum disorders ‐ PMR, steroid
myopathy, vitamin D defic or primary muscle diseases)

• If muscle sx’s resolve and no contraindication:
• Retrial statin at same or lower dose

Troubleshooting‐ Muscle Sx’s
• If recurrence‐ stop statin & wait for sx’s to resolve
• Try low dose of a different statin
• If tolerated, gradually increase dose to target intensity

• If sx’s or elevated CK persist > 2 mos off statin consider other causes
of muscle symptoms (previous slide)
• If sx’s unrelated to statin therapy, or if the predisposing condition has been
treated, resume statin therapy at the original dose

•
Case of myopathy

Summary

Table of Contents: Managing rx
• Monitoring statins with blood work
• What to do with muscle symptoms
• Non‐statins
• Cases
Summary

15

3/17/2014

Non‐statins for ASCVD Reduction?
• No data for routine use of adding nonstatin drugs to reduce ASCVD
events
• No data for ASCVD outcomes in statin‐intolerant pts
• For high‐risk patients with poor response to statins OR intolerance to
appropriate statin intensity:
Consider the addition of a nonstatin cholesterol‐lowering therapy (IIb
C)

Non‐statins
• No gemfibrozil plus statin (IIIB‐ mod evidence of harm)
• Others (bile‐acid sequestrants, niacin, ezetimibe) reasonable in some
cases (Expert opinion)
• Fenofibrate plus low‐ or mod‐intensity statin if :
• benefits from ASCVD risk reduction OR
• TG reduction (esp if TG >500 mg/dL)
… outweigh risk for adverse reactions (IIb C)

• Omega‐3 fatty acids for triglycerides >500 mg/dL
• Should NOT replace statins (IIa B)

• Red Rice yeast‐ no recommendation

Summary

Final Cases
• Mr. Thomas Wheaton
• Statin benefit groups
• Statin intensity goals
• Calculator

• Mrs. Gladys Primpton
• Statin intensity goals

• Ms. Tanya Hilton
• Statin intolerance

• Mr. Jesus Ramos
• Non‐statins

Summary
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Mr. Thomas Wheaton
• 54 y/o AAM without other medical problems
• Exercises 2x/week
• TC‐ 201, LDL‐ 154, HDL‐ 34, TG’s‐ 210
• SBP‐ 119, No tob, no DM2, no HTN rx

• Does Mr. Wheaton need a statin?
• If yes, what intensity?

Mr. Thomas Wheaton

Mr. Thomas Wheaton‐ revised
• 54 y/o AAM without other medical problems
• Exercises 2x/week
• TC‐ 201, LDL‐ 154, HDL‐ 34, TG’s‐ 210
• SBP‐ 135, No tob, no DM2, no HTN rx

• Does Mr. Wheaton need a statin?
• If yes, what intensity?
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Key Recs‐ 4 Major Statin Benefit Groups
Group

Statin intensity

Evidence

Women & men with clinical ASCVD* <75 y/o

High‐intensity

IA

Adults ≥21 years of age with primary LDL–C
≥190 mg/dL

High‐intensity

IB

Adults 40 to 75 years of age with diabetes
mellitus and no clinical ASCVD

Mod‐ intensity

IA

‐ If ASCVD risk ≥7.5%

High‐intensity

IIa B

Adults 40 to 75 years of age with LDL–C 70 to
189 mg/dL, without clinical ASCVD* or
diabetes and a 10‐year ASCVD risk ≥7.5%

Mod‐to‐high

IA

*Clinical ASCVD includes acute coronary syndromes, history of MI, stable or
unstable angina, coronary or other arterial revascularization, stroke, TIA, or
peripheral arterial disease presumed to be of atherosclerotic origin.

Mr. Thomas Wheaton
• What agent?
• What dose?
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Key Recs‐

Statin intensity

Specific statins and doses are noted in bold that were evaluated in RCTs. All of these RCTs demonstrated a
reduction in major cardiovascular events. Statins and doses that are approved by the U.S. FDA but were not
tested in the RCTs reviewed are listed in italics.
*Individual responses to statin therapy varied in the RCTs and should be expected to vary in clinical practice.
There might be a biologic basis for a less‐than‐average response.

Mr. Thomas Wheaton
• Lipid panel after you start statin:
TC‐ 180, LDL‐ 124, HDL‐ 32, TG’s‐ 195
(pre‐statin: TC‐ 201, LDL‐ 154, HDL‐ 34, TG’s‐ 210)

• What is your next step?

Final cases

Summary

Mrs. Gladys Primpton
• 69 y/o WF with h/o CAD, 2 yrs s/p MI and 2 stents
• On atorvastatin 10mg daily, tolerating it well
• PMH: HTN, OA
• Other rx: metoprolol BID, plavix, glucosamine
• Lipid panel:
TC: 150, LDL: 85, HDL: 41 , TG: 130
• What is your next step re: Gladys’s statin?

Final cases

Summary
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Ms. Tanya Hilton
• 65 y/o AAF with h/o CVA
• Minimal residual deficit (L hand weakness and numbness)

• PMH: HTN, HLP, chronic LBP with OA
• SH: former smoker, mod EtOH, rare exercise
• Rx: fosinopril, amlodipine, rosuvastatin 20 mg
• Presents to your office with 2 weeks of progressive muscle aches,
fatigue
• What are your next steps?

Troubleshooting muscle symptoms

Ms. Tanya Hilton
• Stop the statin
• Labs: CK, TSH, vit D 25‐OH, CMP, ESR
• Anything else?
• Labs normal except Vit D 25‐OH of 15
• After 6 weeks of treatment with Vit D, restart statin

Final cases

Summary

Mr. Jesus Ramos
• 35 y/o hispanic male with FHx hereditary hyperlipidemia
• PMH: nothing
• Rx: none
• TC: 300, LDL: 210, HDL: 50, TG: 650
• How would you proceed in treating him?
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Mr. Jesus Ramos
• No definite answers
• High‐intensity statin indicated
• Could add omega‐3 fatty acids
• Could use fenofibrate and mod‐intensity statin
• Consider bile‐acid sequestrants, niacin, ezetimibe

Final cases

Summary

Summary


Statins ‐ strong evidence for ASCVD reduction
 4 benefit groups
 Differing statin intensities



Pooled Risk equation for determing risk of ASCVD



Shared decision‐making when evidence unclear

Secondary causes of hyperlipidemia

Q&A

Contact Info:
Drew_m.Keister@lvhn.org
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Secondary causes of Hyperlipidemia

Back to slide 29

Back to Summary
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